These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. [Justified hope after 4 years. Initial therapy still without resistance]. MMW Fortschr Med; 2003 Apr; 145 Spec No 1():48-9. PubMed ID: 15011588 [No Abstract] [Full Text] [Related]
16. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055 [No Abstract] [Full Text] [Related]
17. Hepatitis coinfection and LPV/RTV. Carter M IAPAC Mon; 2004 Oct; 10(10):398. PubMed ID: 15801120 [No Abstract] [Full Text] [Related]
18. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990 [TBL] [Abstract][Full Text] [Related]
19. Drug interactions. Kaletra and ezetimibe. TreatmentUpdate; 2006; 18(3):8. PubMed ID: 17209242 [No Abstract] [Full Text] [Related]
20. Drug interactions. Kaletra and atazanavir. TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919 [No Abstract] [Full Text] [Related] [Next] [New Search]